PL2764140T3 - Modulacja specyficzności polipeptydów ustrukturyzowanych - Google Patents
Modulacja specyficzności polipeptydów ustrukturyzowanychInfo
- Publication number
- PL2764140T3 PL2764140T3 PL12778672T PL12778672T PL2764140T3 PL 2764140 T3 PL2764140 T3 PL 2764140T3 PL 12778672 T PL12778672 T PL 12778672T PL 12778672 T PL12778672 T PL 12778672T PL 2764140 T3 PL2764140 T3 PL 2764140T3
- Authority
- PL
- Poland
- Prior art keywords
- modulation
- polypeptide specificity
- structured polypeptide
- structured
- specificity
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Analytical Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1117408.3A GB201117408D0 (en) | 2011-10-07 | 2011-10-07 | Modulation of structure polypeptide specificity |
GBGB1205612.3A GB201205612D0 (en) | 2012-03-29 | 2012-03-29 | Modulation of structured polypeptide specificity |
PCT/EP2012/069898 WO2013050616A1 (en) | 2011-10-07 | 2012-10-08 | Modulation of structured polypeptide specificity |
EP12778672.1A EP2764140B1 (en) | 2011-10-07 | 2012-10-08 | Modulation of structured polypeptide specificity |
Publications (1)
Publication Number | Publication Date |
---|---|
PL2764140T3 true PL2764140T3 (pl) | 2018-04-30 |
Family
ID=47080465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL12778672T PL2764140T3 (pl) | 2011-10-07 | 2012-10-08 | Modulacja specyficzności polipeptydów ustrukturyzowanych |
Country Status (21)
Country | Link |
---|---|
US (3) | US10800813B2 (pl) |
EP (2) | EP3299377B1 (pl) |
JP (3) | JP6254527B2 (pl) |
CN (1) | CN103906865B (pl) |
AU (1) | AU2012320407B2 (pl) |
BR (1) | BR112014008156A2 (pl) |
CA (1) | CA2849948C (pl) |
CY (1) | CY1123865T1 (pl) |
DK (1) | DK2764140T3 (pl) |
ES (1) | ES2650625T3 (pl) |
HK (1) | HK1252864A1 (pl) |
HR (1) | HRP20210394T1 (pl) |
HU (1) | HUE053389T2 (pl) |
LT (1) | LT3299377T (pl) |
NO (1) | NO2764140T3 (pl) |
PL (1) | PL2764140T3 (pl) |
PT (1) | PT2764140T (pl) |
RU (2) | RU2745572C2 (pl) |
SG (1) | SG11201400888TA (pl) |
SI (1) | SI3299377T1 (pl) |
WO (2) | WO2013050615A1 (pl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2764140T3 (en) * | 2011-10-07 | 2017-12-04 | Bicyclerd Ltd | MODULATION OF STRUCTURED POLYPEPTIME SPECIFICITY |
ES2755104T3 (es) * | 2012-05-17 | 2020-04-21 | Ra Pharmaceuticals Inc | Inhibidores peptídicos y peptidomiméticos |
GB201306623D0 (en) * | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
WO2015063465A2 (en) * | 2013-10-28 | 2015-05-07 | Bicycle Therapeutics Limited | Novel polypeptides |
AU2015340300B2 (en) | 2014-10-29 | 2019-12-05 | Bicyclerd Limited | Bicyclic peptide ligands specific for MT1-MMP |
WO2017124066A1 (en) * | 2016-01-14 | 2017-07-20 | Arrowhead Pharmaceuticals, Inc. | Method of modifying a peptide |
GB201607827D0 (en) * | 2016-05-04 | 2016-06-15 | Bicycle Therapeutics Ltd | Bicyclic peptide-toxin conjugates specific for MT1-MMP |
WO2018096365A1 (en) | 2016-11-27 | 2018-05-31 | Bicyclerd Limited | Methods for treating cancer |
KR20230042153A (ko) * | 2016-12-23 | 2023-03-27 | 바이사이클티엑스 리미티드 | Mt1-mmp에 대한 결합용 펩티드 리간드 |
US11730819B2 (en) | 2016-12-23 | 2023-08-22 | Bicycletx Limited | Peptide derivatives having novel linkage structures |
WO2018127699A1 (en) * | 2017-01-06 | 2018-07-12 | Bicyclerd Limited | Compounds for treating cancer |
US11499008B2 (en) * | 2017-02-02 | 2022-11-15 | University Of Akron | Functionalized poly (propylene fumarate) polymers made by ring opening polymerization using magnesium catalysts |
EP3585420A4 (en) | 2017-02-22 | 2021-04-07 | Bioincept LLC | PEPTIDES AND METHODS OF TREATMENT OF DYSTROPHY RELATED CONDITIONS USING THEM |
JP7301757B2 (ja) * | 2017-06-26 | 2023-07-03 | バイスクルアールディー・リミテッド | 検出可能部分を持つ二環式ペプチドリガンドおよびその使用 |
CA3071012A1 (en) | 2017-07-17 | 2019-01-24 | Bioincept, Llc | Peptides and methods of transplantation and restorative organ function |
US20200291096A1 (en) * | 2017-08-14 | 2020-09-17 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
CN108191955B (zh) * | 2018-01-11 | 2020-05-19 | 中国科学院化学研究所 | 一种肽两亲分子及其制备方法与应用 |
US11453703B2 (en) * | 2018-04-04 | 2022-09-27 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
GB201808835D0 (en) * | 2018-05-30 | 2018-07-11 | Bicyclerd Ltd | Ligands and methods of selecting binding targets for such |
GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
US11180531B2 (en) * | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
JP2022500404A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 置換ベンゾアゼピン化合物、そのコンジュゲートおよび使用 |
JP2022500414A (ja) | 2018-09-12 | 2022-01-04 | シルバーバック セラピューティックス インコーポレイテッド | 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物 |
US10919937B2 (en) | 2018-10-23 | 2021-02-16 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
CN109627301B (zh) * | 2019-02-18 | 2022-08-05 | 浙江新银象生物工程有限公司 | Nisin固体稳定剂开发及应用 |
US20220267379A1 (en) * | 2019-07-15 | 2022-08-25 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel inhibitors of kallikrein proteases and uses thereof |
TW202110485A (zh) | 2019-07-30 | 2021-03-16 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
KR20220058555A (ko) | 2019-08-15 | 2022-05-09 | 실버백 테라퓨틱스, 인크. | 벤즈아제핀 접합체의 제형 및 이의 용도 |
US11332500B2 (en) | 2019-10-03 | 2022-05-17 | Bicycletx Limited | Heterotandem bicyclic peptide complexes |
WO2021198534A1 (en) | 2020-04-04 | 2021-10-07 | Oxurion NV | Plasma kallikrein inhibitors for use in the treatment of coronaviral disease |
WO2023144030A1 (en) | 2022-01-31 | 2023-08-03 | Oxurion NV | Plasma kallikrein inhibitor therapy for anti-vegf sensitization |
WO2023148016A1 (en) | 2022-02-04 | 2023-08-10 | Oxurion NV | Biomarker for plasma kallikrein inhibitor therapy response |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2145233C1 (ru) * | 1990-07-02 | 2000-02-10 | Дзе Аризона Борд оф Риджентс | Неупорядоченная библиотека пептидов, способ ее получения и способ идентификации пептида, синтезированного твердофазным синтезом |
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
US20030166003A1 (en) | 1999-06-14 | 2003-09-04 | Cochran Andrea G. | Structured peptide scaffold for displaying turn libraries on phage |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
WO2005122379A2 (en) | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
NZ560504A (en) | 2005-01-24 | 2009-07-31 | Pepscan Systems Bv | Binding compounds, immunogenic compounds and peptidomimetics |
PL2374472T3 (pl) | 2006-03-16 | 2018-11-30 | Dyax Corp. | Kompozycje i sposoby leczenia zaburzeń okulistycznych |
EP2052253A2 (en) * | 2006-07-26 | 2009-04-29 | Pepscan Systems B.V. | Immunogenic compounds and protein mimics |
EP2653544A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
GB0913775D0 (en) | 2009-08-06 | 2009-09-16 | Medical Res Council | Multispecific peptides |
GB0914110D0 (en) | 2009-08-12 | 2009-09-16 | Medical Res Council | Peptide libraries |
US20140256590A1 (en) | 2011-08-09 | 2014-09-11 | Vereniging Voor Christelijk Hoger Onderwijs | Method of analysing a blood sample of a subject for the presence of a foetal disease or condition marker |
GB201117428D0 (en) | 2011-10-07 | 2011-11-23 | Bicycle Therapeutics Ltd | Structured polypeptides with sarcosine linkers |
DK2764140T3 (en) * | 2011-10-07 | 2017-12-04 | Bicyclerd Ltd | MODULATION OF STRUCTURED POLYPEPTIME SPECIFICITY |
US20140274759A1 (en) | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
GB201306623D0 (en) * | 2013-04-11 | 2013-05-29 | Bicycle Therapeutics Ltd | Modulation of structured polypeptide specificity |
WO2015063465A2 (en) | 2013-10-28 | 2015-05-07 | Bicycle Therapeutics Limited | Novel polypeptides |
-
2012
- 2012-10-08 DK DK12778672.1T patent/DK2764140T3/en active
- 2012-10-08 WO PCT/EP2012/069897 patent/WO2013050615A1/en active Application Filing
- 2012-10-08 HU HUE17188298A patent/HUE053389T2/hu unknown
- 2012-10-08 RU RU2017132824A patent/RU2745572C2/ru active
- 2012-10-08 EP EP17188298.8A patent/EP3299377B1/en active Active
- 2012-10-08 LT LTEP17188298.8T patent/LT3299377T/lt unknown
- 2012-10-08 US US14/350,192 patent/US10800813B2/en active Active
- 2012-10-08 US US14/350,263 patent/US9994617B2/en active Active
- 2012-10-08 CA CA2849948A patent/CA2849948C/en active Active
- 2012-10-08 RU RU2014118461A patent/RU2631931C2/ru active
- 2012-10-08 CN CN201280049406.8A patent/CN103906865B/zh active Active
- 2012-10-08 AU AU2012320407A patent/AU2012320407B2/en active Active
- 2012-10-08 NO NO12778672A patent/NO2764140T3/no unknown
- 2012-10-08 BR BR112014008156A patent/BR112014008156A2/pt not_active Application Discontinuation
- 2012-10-08 PL PL12778672T patent/PL2764140T3/pl unknown
- 2012-10-08 ES ES12778672.1T patent/ES2650625T3/es active Active
- 2012-10-08 PT PT127786721T patent/PT2764140T/pt unknown
- 2012-10-08 SI SI201231892T patent/SI3299377T1/sl unknown
- 2012-10-08 EP EP12778672.1A patent/EP2764140B1/en active Active
- 2012-10-08 SG SG11201400888TA patent/SG11201400888TA/en unknown
- 2012-10-08 JP JP2014533945A patent/JP6254527B2/ja active Active
- 2012-10-08 WO PCT/EP2012/069898 patent/WO2013050616A1/en active Application Filing
-
2017
- 2017-07-31 JP JP2017147687A patent/JP6568161B2/ja active Active
-
2018
- 2018-09-21 HK HK18112198.5A patent/HK1252864A1/zh unknown
-
2019
- 2019-08-01 JP JP2019142001A patent/JP6906571B2/ja active Active
-
2020
- 2020-06-11 US US16/899,192 patent/US11912794B2/en active Active
-
2021
- 2021-02-26 CY CY20211100165T patent/CY1123865T1/el unknown
- 2021-03-08 HR HRP20210394TT patent/HRP20210394T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252864A1 (zh) | 結構化多肽特異性的調控 | |
HUS1900001I1 (hu) | Transztiretin expressziójának módosítása | |
HRP20181440T8 (hr) | Retinoidni liposomi, namijenjeni poboljšavanju moduliranja eksprimiranja hsp47 | |
HK1221172A1 (zh) | 結構化多肽特異性的調控 | |
HK1201555A1 (en) | Antisense modulation of gccr expression gccr | |
EP2595664A4 (en) | MODULATION OF NUCLEAR RETENTION RNA | |
HK1207078A1 (en) | Inhibition of enzymes | |
IL227656A0 (en) | Immunoglobulin site engineering | |
ZA201403108B (en) | Purification of anti-c-met antibodies | |
PT3461895T (pt) | Modulação da expressão de ube3a-ats | |
EP2776564A4 (en) | MODULATION OF TMPRSS6.EXPRESSION | |
PL2753330T3 (pl) | Terapeutyczne zastosowania ektoiny | |
IL228773B (en) | Antisense modulation of b1ptp expression | |
EP3560952C0 (en) | VARIANT OF BPIFB4 PROTEIN | |
EP2625280A4 (en) | MODULATION OF VSEL-TYPE STEM CELLS BY IGF-1 | |
GB201117408D0 (en) | Modulation of structure polypeptide specificity | |
GB201205612D0 (en) | Modulation of structured polypeptide specificity | |
HK1201420A1 (en) | Use of amylase enzyme |